NCT07294261 2025-12-19
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Sun Yat-sen University
Phase 2 Not yet recruiting
Clinical Trials
5 trialsNCT04136535 2025-07-22
PCA
Fudan University
Phase 2 Recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07037680 2025-07-09
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06977828 2025-06-29
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting